Medtronic Reports Better-Than-Expected Q2 Fiscal 2026 Results, Cardiovascular Sales Surge Over 10%

Gelonghui November 18｜Medical device manufacturer Medtronic announced its second-quarter results for the fiscal year 2026, with net sales reaching $8.96 billion, surpassing analysts' expectations of $8.87 billion; adjusted earnings per share were $1.36, also higher than the expected $1.31. During the period, cardiovascular business sales increased by 10.8% year-on-year, reaching $3.44 billion. For the full fiscal year 2026, the company raised the lower limit of its adjusted earnings per share forecast from $5.60 to $5.62, while maintaining the upper limit at $5.66 unchanged; it also increased its full-year organic revenue growth forecast from approximately 5% to approximately 5.5%.